New equity rights for trading, Moberg Pharma AB TO 2 (473/23)
At the request of Moberg Pharma AB, the equity rights will be traded on First
North Growth Market as from September 20, 2023.
Moberg Pharma TO 2
Security name: Moberg Pharma TO 2
----------------------------------
Short name: MOB TO 2
----------------------------------
ISIN code: SE0020678944
----------------------------------
Orderbook ID: 304809
----------------------------------
Terms: For one (1) warrant, the holder has the right to subscribe for one (1)
new B share. Subscription will be at a subscription price equal to 70
percent of the volume-weighted price paid for the Company's ordinary
share during the period from and including May 20, 2024, up to and
including May 31, 2024, but not less than the quota value of the
shares, corresponding to approximately SEK 1.0 per ordinary share.
--------------------------------------------------------------------------------
Subscr June 05, 2024- June 19, 2024
iption
perio
d:
--------------------------------------------------------------------------------
Last June 17, 2024
tradi
ng
day:
--------------------------------------------------------------------------------
For further information about this exchange notice, please contact
iss@nasdaq.com or + 46 8 405 60 00
Nasdaq Stockholm ABNasdaq Stockholm AB: New equity rights for trading, Moberg Pharma AB TO 2 (473/23)
© 2023 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.04. | Notice of Annual General Meeting in Moberg Pharma AB (publ) | ||
| 08.04. | MOBERG PHARMA: Application submitted to include an additional terbinafine supplier | ||
| 19.02. | MOBERG PHARMA: The Nomination Committee's proposal to the Annual General Meeting 2024 | ||
| 13.02. | Moberg Pharma AB: Year-end report 2023 | LAUNCH INITIATED IN SWEDEN
THE YEAR (JAN-DEC 2023)
EBITDA SEK -25.4 million (-17.6)
Operating profit (EBIT) SEK -27.5 million (-20.2)
Profit after tax SEK -21.1 million (-15.7)
Total profit... ► Artikel lesen | |
| 07.02. | Moberg Pharma: MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication | STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
